Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

GTS-21 attenuates loss of body mass, muscle mass, and function in rats having systemic inflammation with and without disuse atrophy.

Schaller SJ, Nagashima M, Schönfelder M, Sasakawa T, Schulz F, Khan MAS, Kem WR, Schneider G, Schlegel J, Lewald H, Blobner M, Jeevendra Martyn JA.

Pflugers Arch. 2018 Nov;470(11):1647-1657. doi: 10.1007/s00424-018-2180-6. Epub 2018 Jul 13.

PMID:
30006848
2.

Brain PET Imaging of α7-nAChR with [18F]ASEM: Reproducibility, Occupancy, Receptor Density, and Changes in Schizophrenia.

Wong DF, Kuwabara H, Horti AG, Roberts JM, Nandi A, Cascella N, Brasic J, Weerts EM, Kitzmiller K, Phan JA, Gapasin L, Sawa A, Valentine H, Wand G, Mishra C, George N, McDonald M, Lesniak W, Holt DP, Azad BB, Dannals RF, Kem W, Freedman R, Gjedde A.

Int J Neuropsychopharmacol. 2018 Jul 1;21(7):656-667. doi: 10.1093/ijnp/pyy021.

3.

Alpha7 nicotinic acetylcholine receptor-specific agonist DMXBA (GTS-21) attenuates Aβ accumulation through suppression of neuronal γ-secretase activity and promotion of microglial amyloid-β phagocytosis and ameliorates cognitive impairment in a mouse model of Alzheimer's disease.

Takata K, Amamiya T, Mizoguchi H, Kawanishi S, Kuroda E, Kitamura R, Ito A, Saito Y, Tawa M, Nagasawa T, Okamoto H, Sugino Y, Takegami S, Kitade T, Toda Y, Kem WR, Kitamura Y, Shimohama S, Ashihara E.

Neurobiol Aging. 2018 Feb;62:197-209. doi: 10.1016/j.neurobiolaging.2017.10.021. Epub 2017 Nov 22.

PMID:
29175709
4.

Effects of a nicotinic agonist on the Brief Psychiatric Rating Scale five-factor subscale model in schizophrenia.

Lewis AS, Olincy A, Buchanan RW, Kem WR, Picciotto MR, Freedman R.

Schizophr Res. 2018 May;195:568-569. doi: 10.1016/j.schres.2017.10.016. Epub 2017 Oct 16. No abstract available.

5.

Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation.

Kem WR, Olincy A, Johnson L, Harris J, Wagner BD, Buchanan RW, Christians U, Freedman R.

Neuropsychopharmacology. 2018 Feb;43(3):583-589. doi: 10.1038/npp.2017.182. Epub 2017 Aug 21.

6.

An ALPHA7 Nicotinic Acetylcholine Receptor Agonist (GTS-21) Promotes C2C12 Myonuclear Accretion in Association with Release of Interleukin-6 (IL-6) and Improves Survival in Burned Mice.

Khan MAS, Khan MF, Kashiwagi S, Kem WR, Yasuhara S, Kaneki M, Tompkins RG, Martyn JAJ.

Shock. 2017 Aug;48(2):227-235. doi: 10.1097/SHK.0000000000000849.

7.

Brief Report: Initial Trial of Alpha7-Nicotinic Receptor Stimulation in Two Adult Patients with Autism Spectrum Disorder.

Olincy A, Blakeley-Smith A, Johnson L, Kem WR, Freedman R.

J Autism Dev Disord. 2016 Dec;46(12):3812-3817.

PMID:
27565651
8.

Prevention of Burn-Induced Inflammatory Responses and Muscle Wasting by GTS-21, a Specific Agonist for α7 Nicotinic Acetylcholine Receptors.

Kashiwagi S, Khan MA, Yasuhara S, Goto T, Kem WR, Tompkins RG, Kaneki M, Martyn JA.

Shock. 2017 Jan;47(1):61-69.

9.

Activation and Desensitization of Peripheral Muscle and Neuronal Nicotinic Acetylcholine Receptors by Selected, Naturally-Occurring Pyridine Alkaloids.

Green BT, Lee ST, Welch KD, Cook D, Kem WR.

Toxins (Basel). 2016 Jul 4;8(7). pii: E204. doi: 10.3390/toxins8070204.

10.

Recombinant expression and predicted structure of parborlysin, a cytolytic protein from the Antarctic heteronemertine Parborlasia corrugatus.

Butala M, Šega D, Tomc B, Podlesek Z, Kem WR, Küpper FC, Turk T.

Toxicon. 2015 Dec 15;108:32-7. doi: 10.1016/j.toxicon.2015.09.044. Epub 2015 Oct 3.

PMID:
26435341
11.

Non-competitive Inhibition of Nicotinic Acetylcholine Receptors by Ladybird Beetle Alkaloids.

Leong RL, Xing H, Braekman JC, Kem WR.

Neurochem Res. 2015 Oct;40(10):2078-86. doi: 10.1007/s11064-014-1466-0. Epub 2014 Nov 5.

PMID:
25370792
12.

APS8, a polymeric alkylpyridinium salt blocks α7 nAChR and induces apoptosis in non-small cell lung carcinoma.

Zovko A, Viktorsson K, Lewensohn R, Kološa K, Filipič M, Xing H, Kem WR, Paleari L, Turk T.

Mar Drugs. 2013 Jul 16;11(7):2574-94. doi: 10.3390/md11072574.

13.

Point-to-point ligand-receptor interactions across the subunit interface modulate the induction and stabilization of conformational states of alpha7 nAChR by benzylidene anabaseines.

Isaacson MD, Horenstein NA, Stokes C, Kem WR, Papke RL.

Biochem Pharmacol. 2013 Mar 15;85(6):817-28. doi: 10.1016/j.bcp.2013.01.010. Epub 2013 Jan 23.

14.

3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats.

Suzuki S, Kawamata J, Matsushita T, Matsumura A, Hisahara S, Takata K, Kitamura Y, Kem W, Shimohama S.

J Neurosci Res. 2013 Mar;91(3):462-71. doi: 10.1002/jnr.23160. Epub 2012 Dec 14.

PMID:
23239187
15.

Mechanisms of facilitation of synaptic glutamate release by nicotinic agonists in the nucleus of the solitary tract.

Kalappa BI, Feng L, Kem WR, Gusev AG, Uteshev VV.

Am J Physiol Cell Physiol. 2011 Aug;301(2):C347-61. doi: 10.1152/ajpcell.00473.2010. Epub 2011 May 25.

16.

Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia.

Tregellas JR, Tanabe J, Rojas DC, Shatti S, Olincy A, Johnson L, Martin LF, Soti F, Kem WR, Leonard S, Freedman R.

Biol Psychiatry. 2011 Jan 1;69(1):7-11. doi: 10.1016/j.biopsych.2010.07.004. Epub 2010 Aug 21.

17.

Continuous administration of a selective alpha7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice.

Stevens KE, Cornejo B, Adams CE, Zheng L, Yonchek J, Hoffman KL, Christians U, Kem WR.

Brain Res. 2010 Sep 17;1352:140-6. doi: 10.1016/j.brainres.2010.06.063. Epub 2010 Jul 3.

18.

A new phospholipase A2 isolated from the sea anemone Urticina crassicornis - its primary structure and phylogenetic classification.

Razpotnik A, Krizaj I, Sribar J, Kordis D, Macek P, Frangez R, Kem WR, Turk T.

FEBS J. 2010 Jun;277(12):2641-53. doi: 10.1111/j.1742-464X.2010.07674.x.

19.

The odyssey of marine pharmaceuticals: a current pipeline perspective.

Mayer AM, Glaser KB, Cuevas C, Jacobs RS, Kem W, Little RD, McIntosh JM, Newman DJ, Potts BC, Shuster DE.

Trends Pharmacol Sci. 2010 Jun;31(6):255-65. doi: 10.1016/j.tips.2010.02.005. Epub 2010 Apr 2. Review.

PMID:
20363514
20.

A computational study of the binding of 3-(arylidene) anabaseines to two major brain nicotinic acetylcholine receptors and to the acetylcholine binding protein.

Slavov SH, Radzvilovits M, LeFrancois S, Stoyanova-Slavova IB, Soti F, Kem WR, Katritzky AR.

Eur J Med Chem. 2010 Jun;45(6):2433-46. doi: 10.1016/j.ejmech.2010.02.027. Epub 2010 Feb 13.

PMID:
20236734

Supplemental Content

Loading ...
Support Center